|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 7/22/2019 4:49:48 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biomass Programs (Non-Funding)
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
EPA Regulations on Biotechnology
---Efficient Science-Based Reviews of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Regulatory Treatment of Gene Edited Products
FDA Regulations on Biotechnology
---Engineering Biology Research and Development Act (Discussion Draft House)
---Regulatory Treatment of Gene Edited Products
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products
Funding for Biomass Crop Assistance Program
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the USDA
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Genetically Engineered (GE) Animals
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Efficient Science-Based Review of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Genetically Engineered (GE) Plants
---Engineering Biology Research and Development Act (Discussion Draft House)
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Review and Labeling of Food Derived from Biotechnology
The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---Potential Revisions to Part 340 Regulations
---Regulatory Treatment of Gene Edited Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Matthew |
OMara |
|
|
|
Michael |
Mattoon |
|
|
|
Andrew |
Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Efficient Science-Based Review of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Dana |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biofuels
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3163: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Craig Amendment #50
------Perry Amendment #56
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biomass Crop Assistance Program
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biorefineries
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for FDA
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3163: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Aderholt Full Committee Amendment on Germline Editing
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Health Resources and Services Administration (HRSA)
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---340B Program Integrity Issues
---Vaccine Injury Compensation Program (VICP)
Funding for National Institutes of Health
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Renewable Chemicals/Bio-based Products
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the National Vaccine Program Office (NVPO)
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the USDA
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Phyllis |
Arthur |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---Investment Tax Credit
---Production Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---Domestic Manufacturing Requirement
---March-In Rights
Compulsory Licensing
---H.R.465/S.102: Prescription Drug Price Relief Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
Diversity in Patenting
---H.R.6390/S.3483: SUCCESS Act
Drug Patenting
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.440: Preserving Access to Cost Effective Drugs Act (PACED) Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs Act of 2019
Foreign Drug Data Protection Laws
---China
---Saudi Arabia
Intellectual Property International Enforcement
---China
---India
---Malaysia
Inter Partes Review
---H.R.990/S.344 Hatch-Waxman Integrity Act of 2019
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
---S.440: Preserving Access to Cost Effective Drugs Act (PACED) Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---Implementation of the America Invents Act of 2011
Patent Reform
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
---Patent Litigation Reform
Patenting of Biological Inventions
---Argentina Biotech Patentability Guidelines
---DNA Patenting and Licensing
---PTO Examination Guidelines
---Section 101 Modernization
The United States-Mexico-Canada Agreement
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Melissa |
Brand |
|
|
|
Matthew |
OMara |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Shea |
Hartley |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
|
Aiken |
Hackett |
|
|
|
Cameron |
Arterton |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Genetically Engineered (GE) Animals
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Efficient Science-Based Review of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Opioid Crisis
---Coverage and Reimbursement
---FDA Reforms
---Implementation of the SUPPORT for Patients and Communities Act of 2018
---NIH Research
Review and Labeling of Food Derived from Biotechnology
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Dana |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---S.617: Tax Extender and Disaster Relief Act of 2019
---S.1288: Clean Energy for America Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Advanced and Second Generation Biofuels Tax Extenders
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
Biomass Programs (Non-Funding)
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3163: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Craig Amendment #50
------Perry Amendment #56
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biomass Crop Assistance Program
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biorefineries
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Renewable Fuel Standard (RFS)
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---Engineering Biology Research and Development Act (Discussion Draft House)
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Efficient Science-Based Review of Biotech Products
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Review and Labeling of Food Derived from Biotechnology
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Dana |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---S.617: Tax Extender and Disaster Relief Act of 2019
---S.1288: Clean Energy for America Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Advanced and Second Generation Biofuels Tax Extenders
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
Biomass Programs (Non-Funding)
---Engineering Biology Research and Development Act (Discussion Draft House)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3163: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Craig Amendment #50
------Perry Amendment #56
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biomass Crop Assistance Program
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biorefineries
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Renewable Fuel Standard (RFS)
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---Engineering Biology Research and Development Act (Discussion Draft House)
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---340B Optimization Act (Discussion Draft House/Senate)
---340B Pause Act (Discussion Draft House/Senate)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Program Implementation & Oversight
Access to Medicines/World Health Organization
Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Gene Editing
---National Biodefense Strategy
---Pandemic Influenza Preparedness
Biosimilars
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---Access to Samples for Testing
---Patient Cost-Sharing
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---Interchangeability and Pharmacy Substitution
---Medicare Reimbursement
---Naming
Comparative Effectiveness Research Initiatives
---Reauthorization of Patient-Centered Outcomes Research Institute
Diagnostics and Personalized Medicine Regulation and Oversight
---VALID Act (Discussion Draft House)
Drug Evaluation and Review
---FDA Review of CBD-Based Drugs
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Drug Manufacturing, Quality & Distribution
---S.551 REFUND Act of 2019
---Counterfeiting
---Drug Shortages
---Pharmacy Compounding & Oversight
Drug Patenting
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.3199: Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs Act of 2019
Drug Pricing
---General
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act of 2019
---H.R.2069/S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.2113: Prescription Drug STAR Act of 2019
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Pricing Transparency
Foreign Drug Data Protection Laws
---China
---Saudi Arabia
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for FDA
---H.R.3055: Consolidated Appropriations Act of 2019 (which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development Appropriations Bills)
---H.R.3163: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Aderholt Full Committee Amendment on Germline Editing
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Health Resources and Services Administration (HRSA)
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---340B Program Integrity Issues
---Vaccine Injury Compensation Program (VICP)
Funding for National Institutes of Health
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the National Vaccine Program Office (NVPO)
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Generic Drug Entry
---H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---Access to Samples for Testing
---Incentives for Generic Drug Entry
Medicaid
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Arrangements
Medicare Expansion
---S.1129: A bill to establish a Medicare-for-all national health insurance program of 2019
Opioid Crisis
---Coverage and Reimbursement
---FDA Reforms
---Implementation of the SUPPORT for Patients and Communities Act of 2018
---NIH Research
Orphan Drug Issues
---Tax Credit
Precision Medicine Initiative
---Genome Editing
Reimbursement and Coverage of Innovative Products
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---Administration Rebate Rule
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Patient Cost-Sharing
---Protected Classes
---Step Therapy
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
The United States-Mexico-Canada Agreement
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
Vaccine Injury Compensation Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
Vaccines and Infectious Diseases
---H.R.2862/S.1619: Vaccine Awareness Campaign to Champion Immunization Nationally and Enhance Safety (VACCINES) Act of 2019
---S.1872: Protecting Seniors through Immunizations Act of 2019
---Adult Immunization Education
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office, U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Phyllis |
Arthur |
|
|
|
John |
Murphy |
|
|
|
Cameron |
Arterton |
|
|
|
Matt |
O'Mara |
|
|
|
Aiken |
Hackett |
|
|
|
Hans |
Sauer |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Kyle |
Kunkler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Gene Editing
---National Biodefense Strategy
---Pandemic Influenza Preparedness
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Phyllis |
Arthur |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Gene Editing
---National Biodefense Strategy
---Pandemic Influenza Preparedness
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for National Institutes of Health
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Phyllis |
Arthur |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Biosimilars
---Patient Cost-Sharing
---Medicare Reimbursement
Medicaid
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Arrangements
Medicare Expansion
---S.1129: A bill to establish a Medicare-for-all national health insurance program of 2019
Reimbursement and Coverage of Innovative Products
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---Administration Rebate Rule
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Patient Cost-Sharing
---Protected Classes
---Step Therapy
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Jamie |
Gregorian |
|
|
|
Aiken |
Hackett |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
John |
Murphy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Market Enhancements
---Amended Definition of Smaller Reporting Company
Proxy Advisory Services
---Reintroduction of the Corporate Governance Fairness Act in the Senate
---Corporate Governance Reform and Transparency
---Impact of Policies on Small Public Companies
Sarbanes Oxley Section 404 (b)
---S.452: Fostering Innovation Act of 2019
---Reintroduction of the Fostering Innovation Act in the House of Representatives
---Small Issuer Exemption
Short Selling Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arterton |
|
|
|
Lisa |
Schaefer |
|
|
|
Michael |
Mattoon |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---S.617: Tax Extender and Disaster Relief Act of 2019
---Advanced and Second Generation Biofuels Tax Extenders
Capital Formation Investment Incentives
---Reform of Net Operating Loss Rules
---Reintroduction of the American Innovation Act in the House
---Introduction of the American Innovation Act in the Senate
Orphan Drug Issues
---Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Investment Tax Credit
---Production Tax Credit
Qualified Small Business Stock (QSBS)
Research & Development Tax Credit Reforms
---Expensing of R&D Expenditures
---R&D Payroll Credit
Vaccine Injury Compensation Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cameron |
Arteron |
|
|
|
Aiken |
Hackett |
|
|
|
Michael |
Mattoon |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Committee on Foreign Investment in the United States (CFIUS)
---Foreign Investment Risk Review Modernization Act (FIRRMA) Implementation
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products
Foreign Drug Data Protection Laws
---China
Genetically Engineered (GE) Animals
---International Consistency of Regulation for Gene Edited Products
Genetically Engineered (GE) Plants
---International Consistency of Regulation for Gene Edited Products
Intellectual Property International Enforcement
---China
---Malaysia
---India
The United States-Mexico-Canada Agreement
---IP Provisions
---Ag-Biotech Provisions
US-Japan Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Treasury - Dept of, Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
|
Cameron |
Arterton |
|
|
|
Lisa |
Schaefer |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |